medigraphic.com

2013, Number 3

<< Back

Rev Cuba Endoc 2013; 24 (3)

Drugs for loss of weight and metabolic control in obese persons with type 2 diabetes mellitus

Hernández RJ, Licea PME, Castelo Elías-Calles L

Language: Spanish
References: 180
Page: 323-352
PDF size: 188.82 Kb.


ABSTRACT

Introduction: obesity is a growing complex and multifactoral disease that frequently affects people from sexes, age groups and social segments in almost all the countries regardless of their economic development. It brings about substantial costs for the health care system, particularly when it is linked to type 2 diabetes mellitus. In this regard, it is necessary to optimize the medical treatment for these patients.
Objectives: to describe the drugs that should be used in persons with type 2 diabetes mellitus, who present with overweight or obesity, in order to keep good metabolic control and encourage loss of weight or at least to avoid weight gain.
Development: the association of type 2 diabetes mellitus and excessive weight is well-established. The treatment with hypoglycemic such as sulphonylureas, meglitinides, thiazolidonediones and even insulin, may cause weight gain as a potential secondary effect and therefore, it is necessary to use drugs diminishing the weight gain in these persons.
Conclusions: the use of metformine and insulin analogue called detemir in patients with type 2 diabetes mellitus and body overweight is associated to neutral effect or to modest loss of body weight. The dipeptidyl peptidase-4, sitagliptin and vildagliptin inhibitors have neutral effect on weight whereas the glucagon-like peptide 1 receptor agonists called exenatide and liraglutide as well as amiline analogue called pramlintide encourage loss of weight.


REFERENCES

  1. OMS. Obesidad y sobrepeso. Nota descriptiva N° 311 [homepage en internet]; mayo 2012 [citado 5 de octubre de 2012]. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/index.html

  2. Rodríguez E, López B, López AM, Ortega RM. Prevalencia de sobrepeso y obesidad en adultos españoles. Nutr Hosp. 2011;26:355-63.

  3. González E, Aguilar MJ, García CJ, García PA, Álvarez J, Padilla CA. Prevalencia de sobrepeso y obesidad nutricional e hipertensión arterial y su relación con indicadores antropométricos en una población de escolares de Granada y su provincia. Nutr Hosp. 2011;26:1004-10.

  4. Guedes Pinto D, Rocha Divino G, Silva Rocha Martins AJ, Carvalhal Mourão I, Coelho Maria E. Effects of social and environmental determinants on overweight and obesity among Brazilian schoolchildren from a developing region. Rev Panam Salud Pública. 2011 Oct;30(4):295-302.

  5. Vaidya A, Shakya S, Krettek A. Obesity Prevalence in Nepal: Public Health Challenges in a Low-Income Nation during an Alarming Worldwide Trend. Internat J Environmental Res Public Health. 2010;7:2726-44.

  6. Laux TS, Bert PJ, González M, Unruh M, Aragon A, Torres C. Prevalence of obesity, tobacco use, and alcohol consumption by socioeconomic status among six communities in Nicaragua. Rev Panam Salud Pública. 2012;32:217-25.

  7. Catarina E, Moreira R. Estimates of obesity trends in Brazil, 2006-2009. Internat J Public Health. 2012;57:127-33.

  8. Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J. 2012;33:213-20.

  9. Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200.

  10. Kolcic I, Polašek O, Vuletiæ S. Scale and dynamics of overweight and obesity epidemic in Croatia. Obes Facts. 2010;3:333.

  11. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and Trends in Obesity Among US Adults, 1999-2008. JAMA. 2010;303:235-41.

  12. Pigeot I, Barba G, Chadjigeorgiou C, de Henauw S, Kourides Y, Lissner L, et al. Prevalence and determinants of childhood overweight and obesity in European countries: pooled analysis of the existing surveys within the IDEFICS Consortium. Internat J Obesity. 2009;33:1103-10.

  13. Jiménez S, Díaz ME, Barroso I, Bonet M, Cabrera A, Wong I. Estado nutricional de la población cubana Adulta. Rev Esp Nutr Comunitaria. 2005;11:18-26.

  14. González Sánchez R, Llapur Milián R, Rubio Olivares D. Caracterización de la obesidad en los adolescentes. Rev Cubana Pediatr [serie en Internet]. 2009 Jun [citado 20 de marzo de 2013];81(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034 -75312009000200003&lng=es&nrm=iso&tlng=es

  15. Quirantes AJ, López M, Hernández E, Pérez A. Estilo de vida, desarrollo científico-técnico y obesidad. Rev Cubana Salud Pública [serie en Internet]. 2009 [citado 18 de enero de 2013]; 35(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864 -34662009000300014&lng=es&nrm=iso&tlng=es

  16. Fernández SB, Montoya YA, Viguri R. Sobrepeso y obesidad en menores de 20 años de edad en México. Bol Med Hosp Infant Mex. 2011 Feb;68(1):79-81.

  17. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28:w822-w831.

  18. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity. 2008;16:2323-30.

  19. Müller-Riemenschneider F, Reinhold T, Berghöfer A, Willich SN. Health-economic burden of obesity in Europe. Eur J Epidemiol. 2008;23:499-509.

  20. Ferraris F, Beratarrechea A, Llera J, Marchetti M, Perman G. Utilización de recursos y costos médicos directos de las enfermedades crónicas en una población pediátrica argentina. Arch Argent Pediatr. 2011;109:213-8.

  21. García JF, García A, Rodríguez GA, Gálvez AM. Dimensión económica del sobrepeso y la obesidad como problemas de salud pública. Salud en Tabasco. 2010;16:891-5.

  22. Mendivil ACO, Sierra AID. Avances en obesidad. Rev Fac Med Univ Nac Colombia. 2004;52:270-86.

  23. Han JC, Lawlor DA, Kimm SYS. Childhood obesity. Lancet. 2010;375 (9727):1737-48.

  24. Thaler JP, Schwartz MW. Min review: Inflammation and Obesity Pathogenesis: The Hypothalamus Heats Up. Endocrinology. 2010;151:4109-15.

  25. Salas-Salvadó J, Rubio MA, Barbany M, Moreno B y Grupo Colaborativo de la SEEDO. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc). 2007;128:184-96.

  26. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atherosclerosis Thrombosis. 2011;18:629-39.

  27. Frazier-Wood AC, Glasser S, Garvey WT, Kabagambe EK, Borecki IB, Tiwari HK, et al. A clustering analysis of lipoprotein diameters in the metabolic syndrome. Lipids Health Dis. 2011;10:237.

  28. Mokhlesi B. Obesity hypoventilation syndrome: a state-ofthe-art review. Respiratory Care. 2010;55:1347-62.

  29. Hou L, Shu XO, Gao YT, Ji BT, Weiss JM, Yang G, et al. Anthropometric measurements, physical activity, and the risk of symptomatic gallstone disease in Chinese women. Ann Epidemiol. 2009;19:344-50.

  30. Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opinion Lipidology. 2011;22:479-88.

  31. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-78.

  32. Qiao Q, Nyamdorj R. Is the association of type II diabetes with waist circumference or waist-to-hip ratio stronger than that with body mass index. Eur J Clin Nutrition. 2010;64:30-4.

  33. Pausova Z, Mahboubi A, Abrahamowicz M, Leonard GT, Perron M, Richer L, et al. Sex differences in the contributions of visceral and total body fat to blood pressure in adolescence. Hypertension. 2012;59:572-9.

  34. Toss F, Wiklund P, Franks PW, Eriksson M, Gustafson Y, Hallmans G, et al. Abdominal and gynoid adiposity and the risk of stroke. Internat J Obesity. 2011;35:1427-32.

  35. Leinum CJ, Dopp JM, Morgan BJ. Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment. Nutrition Clin Practice. 2009;24:675-87.

  36. Tajer Carlos D. La obesidad y sus paradojas: tratando de elaborar un mensaje coherente para la prevención secundaria. Rev argent cardiol. 2012 Abr;80(2):195-204.

  37. Menéndez E, Lafita J, Artola S, Millán J, Alonso Á, Puig M, et al. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Av Diabetol. 2010;26:331-8.

  38. Yang W, Lu J, Weng J, Weng J, Jia W, Ji L, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090-101.

  39. Farag YMK, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011;26:28-35.

  40. IDF. IDF Diabetes Atlas (fifth edition) [homepage en Internet]; update 2012 [citado 13 de enero de 2013]. Disponible en: http://www.idf.org/diabetesatlas/5e/Update2012

  41. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Practice. 2010;87:4-14.

  42. Arnold Y, Castelo L, Licea M, Medina I. Comportamiento de indicadores epidemiológicos de morbilidad por diabetes mellitus en Cuba, 1998-2009. Rev Perú Epidemiol. 2012;16:1-6.

  43. Arnold Y, Licea M, Aldana D. Algunos aspectos relevantes de la epidemiología de la diabetes mellitus en Cuba. Rev Perú Epidemiol. 2011;15(3):7.

  44. Ministerio de Salud Pública. Registro Nacional de Dispensarización en Diabetes Mellitus. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2009.

  45. Ministerio de Salud Pública. Anuario Estadístico de 2010. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2010.

  46. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;6:737-47.

  47. Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973;29:457-96.

  48. Salvador J, Escalada J. Importancia del control del peso en el deterioro metabólico de la diabetes tipo 2. Av Diabetol. 2010;26:151-5.

  49. Blancas G, Almanza JC, López RI, Alarcón FJ, García R, Cruz M. La obesidad como un proceso inflamatorio. Bol Med Hosp Infant Mex. 2010;67(2):88-97.

  50. Laguna S, Principe RM, Botella S, Santos S, Pizarro M, Fruhbeck G, et al. La diabesidad existe. El índice de masa corporal y la circunferencia abdominal infraestiman el diagnóstico de obesidad en pacientes con diabetes tipo 2. Av Diabetol. 2009;25(Suppl. 1):85-6.

  51. Meneghini L F, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, Ross SA. Weight Beneficial Treatments for Type 2 Diabetes. J Clin Endocrinol Metab. 2011;96:3337-53.

  52. Bajaj M, Baig R, Suraamornkul S, Hardies LJ, Coletta D, Cline G. Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2010;95:1916-23.

  53. Rivas E, Zerquera G, Hernández C, Vicente B. Manejo práctico del paciente con diabetes mellitus en la Atención Primaria de Salud. Rev Finlay. 2011;1:48-64.

  54. Peters AL. Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med. 2009;76(Suppl 5):S20-S27.

  55. Campbell IW. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract. 2010;64:791-801.

  56. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121:94-107.

  57. Salazar Y. Uso de la metformina en la diabetes mellitus tipo II. Rev Cubana de Farmacia. 2011;45:157-66.

  58. Medzinische KI, Vinzentius KL. Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes. Dutch Med Wochenschr. 2010 May;135:907-10.

  59. Sharma MD, Garber AJ. What is the best treatment for Prediabetes? Curr Diab Rep. 2009;9:335-41.

  60. Crespo S. Metformina, a 50 años de su uso: eficacia, tolerancia, seguridad y nuevas indicaciones. Rev Cient Cienc Med. 2009;12:23-5.

  61. Almaguer A, Miguel PE, Será CR, Mariño AL, Oliveros Guerra RC. Actualización sobre diabetes mellitus. Correo Científico Médico. 2012;16:1560-4381.

  62. Expertos de la Sociedad Argentina de Diabetes. Sociedad Argentina de Diabetes A.C. Guía del tratamiento de la diabetes mellitus tipo 2. Rev Soc Arg de Diabetes. 2010;44:359-84.

  63. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063-9.

  64. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43:920-8.

  65. Abbasi F, Carantoni M, Kamath V, Rizvi A, Chen Y-D, Reaven G. Results of a placebo-controlled study of the metabolic effect of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care. 1997;20:1863-9.

  66. Herman W, Hoerger T, Brandle M, Hicks K, Sorensen S, Zhang P. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. Ann Intern Med. 2005;142:323-32.

  67. Hundal R, Inzucchi SE. Metformin: New Concepts, New Uses. Drugs. 2003;63:1879-94.

  68. Iki-Jarvinen H. Metformin Prevents Weight Gain By Reducing Dietary Intake During Insulin Therapy In Patients With Type 2 Diabetes Mellitus. Drugs. 1999;(Suppl 1):53-4.

  69. Johanssen K. Efficacy of Metformin in the Treatment of NIDDM. Meta-Analysis. Diabetes Care. 1999;22:33-7.

  70. Hernández A, Torres O, Carrasco B, Nasiff A, Castelo L, Pérez L, et al. Tratamiento farmacológico de la prediabetes. Rev Cubana Endocrinol. 2011;22:36-45.

  71. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Scien-tific review. JAMA. 2002;287:360-72.

  72. Crespo S. Metformina, a 50 años de su uso: eficacia, tolerancia, seguridad y nuevas indicaciones. Rev Cient Cienc Med. 2009;12:23-5.

  73. Bloomgarden ZT. Approaches to Treatment of Type 2 Diabetes. Diabetes Care. 2008;31:1697-703.

  74. Martin MC, Díaz JM, Muros JM, González A, Costa P. Metformina en el tratamiento de la diabetes tipo 2 con sobrepeso u obesidad. Ann Med Intern. 2005;22:579-85.

  75. Prado AB, Gaete PV, Corona HF, Peralta VE, Donoso AP, Raimann TX. Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2. Rev chil pediatr. 2012 Feb;83(1):48-57.

  76. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

  77. UK Prospective Diabetes Study Group: effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.

  78. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-97.

  79. Feliciano JE, Sierra ID. Nuevas terapias en Diabetes: más allá de la insulina inyectable y de los antidiabéticos orales. Rev Assoc Med Bras. 2008;54:447-54.

  80. González M, Pereg V, Burgera YB. Novedades en terapia hipoglucemiante. Fármacos con acción incretina. Endocrinol Nutr. 2008;55(Supl 2):73-7.

  81. Di Girolamo G, Tamez AL, Tamez HE. Inhibidores de la dipeptidil peptidasa-4: farmacodinamia, farmacocinética y seguridad. Med Int Mex. 2008;24:142-7.

  82. Holst JJ, Vilsbøll T, Deacon C. The incretin system and its role in type 2diabetes mellitus. Mol Cell Endocrinol. 2009;297:127-36.

  83. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic propertiesof incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol. 2008;158:773-84.

  84. Vilsbøll T, Garber AJ. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab. 2012;14 Suppl 2:41-249.

  85. Davidson JA. Incorporating incretin-based therapies into clinical practice: difference between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase inhibitors. Mayo Clin Proc. 2010;85:S27-S37.

  86. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:511-27.

  87. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol. 2010;25:1207-17.

  88. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, and for the LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.

  89. Campbell RK, Cobble ME, Reid TS, Shomali ME. Safety, tolerability and non-glycemic effects of incretin-based therapies. J Fam Pract. 2010;59:S1:S5-S9.

  90. Blonde L, Montanya E. Comparison of liraglutide versus other incretin related anti-hyperglycemic agents. Diabetes Obes Metab. 2012;14(Suppl 2):20-32.

  91. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-86.

  92. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications ofrecent clinical trials. Ann Intern Med. 2011;154:554-9.

  93. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA (1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481-9.

  94. Plutzky J. The Incretin Axis in Cardiovascular Disease Circulation. 2011;124:2285-9.

  95. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.

  96. Garber A, Henry R, Ratner R, Garcia PA, Rodriguez H, Olvera H, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-81.

  97. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. Diabetologia. 2009;52:2046-55.

  98. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz SH, Raskin PH, et al. Efficacy and safety of the human glucagon-like peptide 1 analog liraglutide in combination with metformin and thiazolidinediones in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-30.

  99. Moretto TJ, Milton DR, Ridge TD, MacConell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. ClinTher. 2008;30:1448-60.

  100. Davidson JA, Parente EB, Gross JL. Incretin mimetics and dipeptidil peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arq Bras Enocrinol Metabol. 2008;52:1039-49.

  101. Verge D, López X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev. 2010;6:191-200.

  102. Mafong DD, Henry RR. The role of incretins in cardiovascular control. Curr Hypertens Rep. 2009;11:18-22.

  103. Ross SA, Ekoé JM. Incretin agents in type 2 diabetes. Can Fam Physician. 2010;56:639-48.

  104. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Reviews. 2011;27:528-42.

  105. Kim D, Kowalchick JE, Edmondson SD, Mastracchio A, Xu J, Eiermann GJ, et al. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogues of JANUVIA (sitagliptin phosphate). Bioorg Med Chem Lett. 2007;17:3373-7.

  106. Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Invest Drugs. 2007;16:533-45.

  107. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187-218.

  108. Choy M, Lam S. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Cardiol Rev. 2007;15:264-71.

  109. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144:5145-8.

  110. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-40.

  111. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711-21.

  112. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and a meta-analysis. JAMA. 2007;29:194-206.

  113. Agencia Española de Medicamentos y Productos Sanitarios. Informe mensual sobre medicamentos de uso humano y productos sanitarios [homepage en Internet]; Septiembre 2011 [citado 10 de enero de 2013]. Disponible en: http://www.aemps.gob.es/informa/informeMensual/2011 /septiembre/informe-medicamentos.htm#p1

  114. Committee for medical products for human use (CHMP). Komboglyze EMA/CHMP/755839/2011 [homepage en Internet]; Septiembre 2011 [citado 10 de enero de 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation /human/002059/WC500112846.pdf

  115. Di Girolamo G, Tamez AL, Tamez HE. Inhibidores de la dipeptidil peptidasa-4: farmacodinamia, farmacocinética y seguridad. Medicina Mex. 2008;24:142-7.

  116. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-80.

  117. Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A. Vidagliptin as add on to insulin in patients with type 2 diabetes (T2DM):467-P (article). Diabetes. 2006;55(Suppl 1):A111.

  118. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, on-inferiority trial. Diabetes Obes Metab. 2007;9:194-205.

  119. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979-87.

  120. Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ. Curr Med Res Opinion. 2011;27:1431-8.

  121. Green BD, Gault VA, O'Harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin tropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des. 2004;10:3651-62.

  122. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept. 2005;128:135-48.

  123. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synteticexendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.

  124. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-9.

  125. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123-9.

  126. Keating GM. Exenatide. Drugs. 2005;65:1681-92.

  127. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376(9739):431-9.

  128. Folli F, Guardado R. Potential use of exenatide for the treatment of obesity Expert Opinion on Investigational. Drugs. 2011;20:1717-22.

  129. Plutzky J. The Incretin Axis in Cardiovascular Disease. Circulation. 2011;124:2285-9.

  130. Blonde L, Montanya E. Comparison of liraglutide versus other incretin related anti-hyperglycemic agents. Diabetes Obes Metab. 2012;14(Suppl 2):20-32.

  131. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz SH, Raskin PH; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide 1 analog liraglutide in combination with metformin and thiazolidinediones in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-30.

  132. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol. 2010;25:1207-17.

  133. Davidson JA, Parente EB, Gross JL. Incretin mimetics and dipeptidil peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arq Bras Enocrinol Metabol. 2008;52:1039-49.

  134. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm. 2005;62:173-81.

  135. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279-S284.

  136. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.

  137. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effect of once-weekly dosing of a long-acing release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-93.

  138. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects ofexenatine (exendin-4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.

  139. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformine-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.

  140. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS. Effects of exenatide (exendin-4) on glycemic control over 30 weeks inpatients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.

  141. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obesity Metabolism. 2011;13:559-66.

  142. Rosenstock J, Klaff LJ, Schwartz Sh, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes. Diabetes Care. 2010;33:1173-5.

  143. Tzefos M, Olin JL. Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus. Ann Pharmacother. 2010;44:1294-300.

  144. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo- controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86:44-57.

  145. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-69.

  146. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice daily exenatide and biphasic insulin aspartat in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non inferiority study. Diabetologia. 2007;50:259-67.

  147. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover non inferiority trial. Clin Ther. 2007;29:2333-48.

  148. Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, Smith-Palmer J, et al. Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitas tipo 2 en España. Endocrinol Nutr. 2011;58:331-40.

  149. Pratley RE, GilbertM. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5:73-594.

  150. Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96:1695-702.

  151. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-78.

  152. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-10.

  153. Deacon CF. Therapeutic strategies based upon glucagon-like peptide 1. Diabetes. 2004;53:2181-9.

  154. Johl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51(2):424-9.

  155. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs. glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26:1013-22.

  156. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5:73-94.

  157. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects ofamylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435-49.

  158. Kruger DF, Aronoff SL, Edelman SV. Through the Looking Glass: Current and Future Perspectives on the Role of Hormonal Interplay in Glucose Homeostasis. Diabetes Educ. 2007;33(Suppl. 2):32S-46S.

  159. Weyer CH, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, et al. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005;62:816-22.

  160. Singh-Franco D, Robles G, Gazze D. Pramlintide acetate injection for thetreatment of type 1 and type 2 diabetes mellitus. Clin Therapeutics. 2007;29:535-62.

  161. Lee NJ, Norris SL, Thakurta S. Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus. Ann Fam Med. 2010;8:542-9.

  162. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977-83.

  163. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009;17:1736-43.

  164. Jones D. Suspense builds on anti-obesity rollercoaster ride. News & analysis. 2011;10:5-6.

  165. Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009;32:1577-82.

  166. Riddle M, Frias J, Zhang , Maier H, Brown C, Lutz K, et al. Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin. Diabetes Care. 2007;30:2794-9.

  167. Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Health Patient Saf. 2010;2:213-23.

  168. Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Health Patient Saf. 2010;2:213-23.

  169. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza Ch, et al. Lower within-subject variability of insulin Detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-20.

  170. Heise T, Pieber TR. Towards peak less, reproducible and long-acting insulin. An assessment of the basal analogues based on isoglycaemic clamps studies. Diabetes Obes Metab. 2007;9:648-59.

  171. Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Invest. 2007;27:279-85.

  172. Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin Detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55:1735-40.

  173. Liu Sh, Liu R, Chiang YT, Song L, Li X, Jin T, et al. Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating â-catenin and CREB activities. AJP-Endo. 2012;303:E740-E751.

  174. Fakhoury W, Lockhart I, Kotchie RW, Aagren M, Lereun C. Indirect comparison of once daily insulin Detemir and Glargine in reducing weight gain and hypoglycemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type 2 diabetes. Pharmacology. 2008;82:156-63.

  175. Hollander PA. Insulin Detemir for the treatment of obese patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:11-9.

  176. Hallschmid M, Jauch-Chara K, Korn O, Matthias M, Björn R, Jan B, et al. Euglycemic infusion of insulin Detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes. 2010;59:1101-7.

  177. Bohm A, Staiger H, Hennige AM, Haas C, Machicao F, Haring HU. Effect of insulin Detemir, compared to human insulin, on 3T3-L1 adipogenesis. Regul Pept. 2008;151:160-3.

  178. PerrielloG, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, et al. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. Expert Opinion on Pharmacotherapy. 2011;12:2449-55.

  179. Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Andreas F, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin Glargine once-daily with insulin Detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33:1176-8.

  180. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin Detemir with insulin Glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-16.




2020     |     www.medigraphic.com